WO2005048928A3 - Methods for treating viral infection - Google Patents

Methods for treating viral infection Download PDF

Info

Publication number
WO2005048928A3
WO2005048928A3 PCT/US2004/037652 US2004037652W WO2005048928A3 WO 2005048928 A3 WO2005048928 A3 WO 2005048928A3 US 2004037652 W US2004037652 W US 2004037652W WO 2005048928 A3 WO2005048928 A3 WO 2005048928A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
growth factor
epidermal growth
viral infection
treating
Prior art date
Application number
PCT/US2004/037652
Other languages
French (fr)
Other versions
WO2005048928A2 (en
Inventor
Raymond Weinstein
Michael Weinstein
Original Assignee
George Mason Intellectual Prop
Raymond Weinstein
Michael Weinstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Mason Intellectual Prop, Raymond Weinstein, Michael Weinstein filed Critical George Mason Intellectual Prop
Publication of WO2005048928A2 publication Critical patent/WO2005048928A2/en
Publication of WO2005048928A3 publication Critical patent/WO2005048928A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention also relates to treating and/or preventing a virus infection, and reactions associated with viral vaccination using tyrosine kinase inhibitors and/or epidermal growth factor receptor blockers. Examples of useful tyrosine kinase inhibitors include, quinazoline derivatives, such as 4-quinazolinamine-N-(3chlor-4-fluorophenyl)-7-methosy-6-[3-4-morpholin)propoxy]. The present invention relates to compositions and methods for treating and/or preventing a viral infection with modulators of epidermal growth factor (“EGF”) and of the epidermal growth factor receptor (“EGFR”) pathway.
PCT/US2004/037652 2003-11-12 2004-11-12 Methods for treating viral infection WO2005048928A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51867803P 2003-11-12 2003-11-12
US60/518,678 2003-11-12

Publications (2)

Publication Number Publication Date
WO2005048928A2 WO2005048928A2 (en) 2005-06-02
WO2005048928A3 true WO2005048928A3 (en) 2006-01-12

Family

ID=34619326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037652 WO2005048928A2 (en) 2003-11-12 2004-11-12 Methods for treating viral infection

Country Status (1)

Country Link
WO (1) WO2005048928A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076375B2 (en) 2005-10-13 2011-12-13 The Salk Institute For Biological Studies Methods of inhibiting poxvirus growth
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
WO2009098061A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
JP5539351B2 (en) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them
US8629153B2 (en) 2008-09-03 2014-01-14 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
JP2012512883A (en) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of epidermal growth factor inhibitors in the treatment of viral infections
CN105687197B (en) * 2016-01-20 2018-05-18 中国人民解放军第二军医大学 Epidermal growth factor receptor inhibitor is preparing the application in treating encephalitis B drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
US20010014328A1 (en) * 1996-07-11 2001-08-16 Mederax, Inc. Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
US20010014328A1 (en) * 1996-07-11 2001-08-16 Mederax, Inc. Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TZAHAR ET AL: "Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.", THE EMBO JOURNAL., vol. 17, no. 20, 1998, pages 5948 - 5963, XP002992988 *

Also Published As

Publication number Publication date
WO2005048928A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2006135636A3 (en) Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
WO2006135649A3 (en) Aminoquinoline and aminoquinazoline kinase modulators
AP2004003058A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth.
WO2006050109A3 (en) Novel kinase inhibitors
EP2331530B8 (en) Fused multicyclic compounds as protein kinase inhibitors
MXPA05007831A (en) Preparation of substituted quinazolines.
WO2010028254A3 (en) Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
BR0215360A (en) Indoline derivatives useful as protein kinase inhibitors
WO2006050965A8 (en) Pyrimidine compounds as histamine modulators
WO2004054514A3 (en) C-6 modified indazolylpyrrolotriazines
HK1082737A1 (en) Triheterocyclic compounds, compositions, and methods for treating cancer
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
WO2007084413A3 (en) Methods for treating hepatitis c
DK1848414T3 (en) Process for the treatment of gefitinib-resistant cancer
WO2004009784A3 (en) Novel inhibitors of kinases
AU2004272348A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
WO2001090103A3 (en) 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
WO2005115145A3 (en) Quinone substituted quinazoline and quinoline kinase inhibitors
MXPA04004492A (en) C-5 modified indazolylpyrrolotriazines.
WO2006135713A3 (en) Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
WO2005048928A3 (en) Methods for treating viral infection
UA85394C2 (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors
ATE547411T1 (en) 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDROINDOLINONE DERIVATIVES AND USES THEREOF
WO2003052072A3 (en) Antisense modulation of estrogen receptor alpha expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase